AARD - Aardvark Therapeutics Inc.
6.11
0.390 6.383%
Share volume: 181,776
Last Updated: 05-12-2026
Pharmaceutical Products/Pharmaceutical Preparations:
0.10%
PREVIOUS CLOSE
CHG
CHG%
$5.72
0.39
0.07%
View ratios
| Fiscal Date | 03-31-2025 | 09-30-2025 | 12-31-2025 | 03-31-2026 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
| Report Date | 05-14-2025 | 11-13-2025 | 03-23-2026 | 05-07-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | ||||
| Operating expenses | 10.470 M | 17.703 M | 18.704 M | 22.464 M | |
| Selling general and admin | 2.715 M | 3.966 M | 4.405 M | 5.897 M | |
| Research and development | 7.755 M | 13.737 M | 14.299 M | 16.567 M | |
| Total expenses | 10.470 M | 17.703 M | 18.704 M | 22.464 M | |
| 69.08% | 5.65% | 20.10% | |||
| Operating income | -10.470 M | -17.703 M | -18.704 M | -22.464 M | |
| Ebit | -10.485 M | -17.667 M | -18.723 M | -22.477 M | |
| Pretax income | -9.310 M | -16.316 M | -17.598 M | -21.588 M | |
| 75.25% | 7.86% | 22.67% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -9.310 M | -16.316 M | -17.598 M | -21.588 M | |
| -75.25% | -7.86% | -22.67% |